The FDA has suspended the U.S. license for Valneva's chikungunya vaccine, Ixchiq, following new reports of serious adverse events including chikungunya-like illnesses in vaccinated individuals. The move mandates an immediate halt to shipments and sales across the U.S., reflecting growing safety concerns despite earlier approvals under accelerated pathways. Valneva’s shares dropped sharply after the announcement.